Cargando…

Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma

Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that predicts response to immunotherapy in LIHC. Therefore, this research seeks to identify immunogenic progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lei, Quan, Wen, Luo, Qiong, Pan, Ying, Peng, Dongxu, Zhang, Guihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542239/
https://www.ncbi.nlm.nih.gov/pubmed/33195412
http://dx.doi.org/10.3389/fmolb.2020.567950
_version_ 1783591516190539776
author Wu, Lei
Quan, Wen
Luo, Qiong
Pan, Ying
Peng, Dongxu
Zhang, Guihai
author_facet Wu, Lei
Quan, Wen
Luo, Qiong
Pan, Ying
Peng, Dongxu
Zhang, Guihai
author_sort Wu, Lei
collection PubMed
description Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that predicts response to immunotherapy in LIHC. Therefore, this research seeks to identify immunogenic prognostic biomarkers and explore potential predictors for the efficacy of anti-PD-1/PD-L1 therapies in LIHC. The clinical data and gene expression profiles of patients diagnosed with LIHC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Moreover, IRGs were obtained from the ImmPort database. We discovered 35 IRGs that were differentially expressed between LIHC tissues and corresponding normal tissues. Through univariate Cox regression analysis, eight prognostic differentially expressed IRGs (PDEIRGs) were identified. Further, three optimal PDEIRGs (BIRC5, LPA, and ROBO1) were identified and used to construct a prognostic risk signature of LIHC patients via multivariate Cox regression analysis. The signature was validated by ROC curves. Subsequently, based on gene set enrichment analysis (GSEA) analysis, two out of the three optimal PDEIRGs (BIRC5 and LPA) were significantly enriched in the mismatch repair (MMR) pathway. Moreover, the two PDEIRGs (BIRC5 and LPA) were significantly correlated with the expression of genes related to mismatch repair (MLH1, MSH2, MSH6, and PMS2). Furthermore, correlations between the two PDEIRGs (BIRC5 and LPA) and immune checkpoints of cancer treatment (such as CTLA4, PD-1, and PD-L1) were demonstrated. Hyperprogressive disease (HPD) is a novel pattern of tumor progression which has a close relationship with immune checkpoint inhibitors (ICIs) utilization. MDM2 family amplification might promote the HPD phenomenon. Finally, we found a positive regulatory relationship between HPD related gene (MDM2) and BIRC5. Notably, MDM2 can either interact directly with BIRC5 or indirectly via downstream transcription factors of BIRC5. Overall, our study uncovered a novel 3-immune-related prognostic genes in LIHC.
format Online
Article
Text
id pubmed-7542239
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75422392020-11-13 Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma Wu, Lei Quan, Wen Luo, Qiong Pan, Ying Peng, Dongxu Zhang, Guihai Front Mol Biosci Molecular Biosciences Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that predicts response to immunotherapy in LIHC. Therefore, this research seeks to identify immunogenic prognostic biomarkers and explore potential predictors for the efficacy of anti-PD-1/PD-L1 therapies in LIHC. The clinical data and gene expression profiles of patients diagnosed with LIHC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Moreover, IRGs were obtained from the ImmPort database. We discovered 35 IRGs that were differentially expressed between LIHC tissues and corresponding normal tissues. Through univariate Cox regression analysis, eight prognostic differentially expressed IRGs (PDEIRGs) were identified. Further, three optimal PDEIRGs (BIRC5, LPA, and ROBO1) were identified and used to construct a prognostic risk signature of LIHC patients via multivariate Cox regression analysis. The signature was validated by ROC curves. Subsequently, based on gene set enrichment analysis (GSEA) analysis, two out of the three optimal PDEIRGs (BIRC5 and LPA) were significantly enriched in the mismatch repair (MMR) pathway. Moreover, the two PDEIRGs (BIRC5 and LPA) were significantly correlated with the expression of genes related to mismatch repair (MLH1, MSH2, MSH6, and PMS2). Furthermore, correlations between the two PDEIRGs (BIRC5 and LPA) and immune checkpoints of cancer treatment (such as CTLA4, PD-1, and PD-L1) were demonstrated. Hyperprogressive disease (HPD) is a novel pattern of tumor progression which has a close relationship with immune checkpoint inhibitors (ICIs) utilization. MDM2 family amplification might promote the HPD phenomenon. Finally, we found a positive regulatory relationship between HPD related gene (MDM2) and BIRC5. Notably, MDM2 can either interact directly with BIRC5 or indirectly via downstream transcription factors of BIRC5. Overall, our study uncovered a novel 3-immune-related prognostic genes in LIHC. Frontiers Media S.A. 2020-09-24 /pmc/articles/PMC7542239/ /pubmed/33195412 http://dx.doi.org/10.3389/fmolb.2020.567950 Text en Copyright © 2020 Wu, Quan, Luo, Pan, Peng and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Wu, Lei
Quan, Wen
Luo, Qiong
Pan, Ying
Peng, Dongxu
Zhang, Guihai
Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
title Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
title_full Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
title_fullStr Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
title_full_unstemmed Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
title_short Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
title_sort identification of an immune-related prognostic predictor in hepatocellular carcinoma
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542239/
https://www.ncbi.nlm.nih.gov/pubmed/33195412
http://dx.doi.org/10.3389/fmolb.2020.567950
work_keys_str_mv AT wulei identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma
AT quanwen identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma
AT luoqiong identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma
AT panying identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma
AT pengdongxu identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma
AT zhangguihai identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma